Carlsbad-based pharmaceuticals developer Isis Pharmaceuticals said Tuesday afternoon that it will receive $1.1M from Alnylam Pharmaceuticals, as a resutl of upfront fees from Alnylam's collaboration with Genzyme. Isis said the additional payments from Alnylam bring its total earned from the company this year to $2.7M. Isis reported a payment in August from Alnylam.